BIOMAT Database Logo BIOMAT Database Logo

Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment. 1993

R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
St John's Institute of Dermatology, UMDS, St Thomas's Hospital, London.

1. Previous, in vitro, studies have established the synthesis of platelet activating factor (PAF) by the 're-modelling' pathways in which the activation of a phospholipase A2 (PLA2) enzyme catalyses the hydrolysis of an ether-acyl-phosphocholine to give concomitant release of lyso-PAF, the immediate precursor of PAF, and arachidonic acid, the precursor of the icosanoids. The aim of this study was to investigate the relationship between PAF and eicosanoid release in human skin, and to study the effect of treatment of skin with a topical steroid, on the release of PAF, lyso-PAF and arachidonic acid. 2. A novel assay procedure was developed for the simultaneous assay of PAF and lyso-PAF in skin exudates from abrasions and suction blisters in normal human skin. In addition we assayed arachidonic acid and prostaglandin E2 (PGE2), a representative eicosanoid. 3. The mean amounts of mediator recovered in the first 30 min period following abrasion were PAF 0.43, lyso-PAF 11.9, PGE2 25.7 and arachidonic acid 760 pmol/sample. The molar ratio of PAF:lyso-PAF:arachidonic acid in skin exudates from abrasions was 1:30:1800 and in suction blister exudates was 1:90:3660. 4. Time course studies showed a decline in the recoveries of arachidonic acid and lyso-PAF, of about 50% in 2 h. In contrast, PAF was recovered in exudates at a constant rate over 2 h but PGE2 release decreased by more than 90% after the initial 30 min period. 5. Topical application under occlusion, of 0.05% clobetasol propionate, a potent corticosteroid, significantly reduced lyso-PAF by 30% in suction blister exudates but did not significantly alter the concentrations of PAF or arachidonic acid.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008401 Gas Chromatography-Mass Spectrometry A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds. Chromatography, Gas-Liquid-Mass Spectrometry,Chromatography, Gas-Mass Spectrometry,GCMS,Spectrometry, Mass-Gas Chromatography,Spectrum Analysis, Mass-Gas Chromatography,Gas-Liquid Chromatography-Mass Spectrometry,Mass Spectrometry-Gas Chromatography,Chromatography, Gas Liquid Mass Spectrometry,Chromatography, Gas Mass Spectrometry,Chromatography, Mass Spectrometry-Gas,Chromatography-Mass Spectrometry, Gas,Chromatography-Mass Spectrometry, Gas-Liquid,Gas Chromatography Mass Spectrometry,Gas Liquid Chromatography Mass Spectrometry,Mass Spectrometry Gas Chromatography,Spectrometries, Mass-Gas Chromatography,Spectrometry, Gas Chromatography-Mass,Spectrometry, Gas-Liquid Chromatography-Mass,Spectrometry, Mass Gas Chromatography,Spectrometry-Gas Chromatography, Mass,Spectrum Analysis, Mass Gas Chromatography
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D001768 Blister Visible accumulations of fluid within or beneath the epidermis. Bulla,Vesication,Bleb,Bullae,Bullous Lesion,Blebs,Blisters,Bullous Lesions,Lesion, Bullous,Lesions, Bullous,Vesications
D002990 Clobetasol A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression. Clobetasol 17-Propionate,Clobetasol Propionate,Clobex,Clofenazon,Cormax,Dermovate,Embeline,Embeline E,OLUX,Temovate,Clobetasol 17 Propionate
D005122 Exudates and Transudates Exudates are fluids, CELLS, or other cellular substances that are slowly discharged from BLOOD VESSELS usually from inflamed tissues. Transudates are fluids that pass through a membrane or squeeze through tissue or into the EXTRACELLULAR SPACE of TISSUES. Transudates are thin and watery and contain few cells or PROTEINS. Transudates,Exudates,Transudates and Exudates,Exudate,Transudate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Evidence for different mechanisms involved in the formation of lyso platelet-activating factor and the calcium-dependent release of arachidonic acid from human neutrophils.
November 1992, Biochemical pharmacology,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Biosynthesis of platelet-activating factor (PAF) in human polymorphonuclear leucocytes. The role of lyso-PAF disposal and free arachidonic acid.
May 1990, The Biochemical journal,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
The lyso-precursor of platelet-activating factor (lyso-PAF) in ischaemic myocardium.
November 1991, Journal of lipid mediators,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Upregulation of Platelet-Activating Factor Receptor Expression and Lyso-Platelet-Activating Factor Isoforms in Human Nasal Polyp Tissues.
November 2023, Journal of clinical medicine,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Release of platelet-activating factor (PAF-acether) and arachidonic acid metabolites from alveolar macrophages.
December 1981, Agents and actions,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Opposing effects of platelet-activating factor and lyso-platelet-activating factor on neutrophil and platelet activation.
January 2009, Molecular pharmacology,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Phospholipid biosynthesis in human platelets. The acylation of lyso-platelet-activating factor.
February 1985, The Biochemical journal,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Stimulation of platelet-activating factor synthesis by a nonmetabolizable bioactive analog of platelet-activating factor and influence of arachidonic acid metabolites.
March 1989, The Journal of biological chemistry,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.
December 1986, British journal of clinical pharmacology,
R M Barr, and F Lawlor, and M R Judge, and P Courtney, and R Barlow, and A Kobza Black, and A I Mallet, and M W Greaves
Presence and metabolism of lyso platelet-activating factor in human bone marrow.
May 1997, Journal of lipid mediators and cell signalling,
Copied contents to your clipboard!